In parallel, we tested combinations of these compounds with temozolomide and lomustine, the standard chemotherapy agents used in GB treatment. Here, we compared the efficacy of focused modulation of a set of signaling pathways in two GB cell lines, U-251 MG and T98-G, using a panel of thirteen compounds targeting cell cycle progression, proliferation, epigenetic modifications, and DNA repair mechanism. To prevent rapid tumor recurrence, targeted strategies for the treatment of GB are widely sought. Despite the use of multimodal treatment combinations, the prognosis of glioblastoma (GB) is still poor.
0 kommentar(er)
